88 related articles for article (PubMed ID: 9369906)
1. [Genetic alteration of lung cancer as a prognostic marker and its therapeutic implications].
Mitsudomi T; Takahashi T
Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():345-52. PubMed ID: 9369906
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
Mitsudomi T; Hamajima N; Ogawa M; Takahashi T
Clin Cancer Res; 2000 Oct; 6(10):4055-63. PubMed ID: 11051256
[TBL] [Abstract][Full Text] [Related]
3. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
4. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
5. Relationship of p53 alteration and myc family gene overexpression with the clinical characteristics of lung cancer.
Bai L; Sun Y; Li S
Chin Med J (Engl); 1997 Apr; 110(4):250-4. PubMed ID: 9594222
[TBL] [Abstract][Full Text] [Related]
6. [Genetic abnormalities in lung cancer and their prognostic implications].
Mitsudomi T; Takahashi T
Gan To Kagaku Ryoho; 1996 Jul; 23(8):990-6. PubMed ID: 8687234
[TBL] [Abstract][Full Text] [Related]
7. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
Murakami I; Hiyama K; Ishioka S; Yamakido M; Kasagi F; Yokosaki Y
Clin Cancer Res; 2000 Feb; 6(2):526-30. PubMed ID: 10690534
[TBL] [Abstract][Full Text] [Related]
10. [Studies on genes associated with biologic behavior in human lung cancer].
Bai L; Sun Y; Li S
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):23-5. PubMed ID: 11263295
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Lung Cancer; 2005 Dec; 50(3):309-17. PubMed ID: 16125276
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
13. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
Tomizawa Y; Kohno T; Fujita T; Kiyama M; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Nakajima T; Yokota J
Oncogene; 1999 Jan; 18(4):1007-14. PubMed ID: 10023676
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma.
Tomizawa Y; Adachi J; Kohno T; Hamada K; Saito R; Noguchi M; Matsuno Y; Hirohashi S; Yamaguchi N; Yokota J
Clin Cancer Res; 1999 May; 5(5):1139-46. PubMed ID: 10353749
[TBL] [Abstract][Full Text] [Related]
15. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
Wang X; Christiani DC; Mark EJ; Nelson H; Wiencke JK; Gunn L; Wain JC; Kelsey KT
Cancer; 1999 Apr; 85(8):1734-9. PubMed ID: 10223567
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer.
Tan DF; Li Q; Rammath N; Beck A; Wiseman S; Anderson T; al-Salameh A; Brooks J; Bepler G
Anticancer Res; 2003; 23(2C):1665-72. PubMed ID: 12820438
[TBL] [Abstract][Full Text] [Related]
17. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation.
Oyama T; Kawamoto T; Mizoue T; Sugio K; Kodama Y; Mitsudomi T; Yasumoto K
Anticancer Res; 1997; 17(1B):583-7. PubMed ID: 9066584
[TBL] [Abstract][Full Text] [Related]
19. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Greco G; Mussi A; Donati V; Fontanini G
Cancer Invest; 2008 Mar; 26(2):168-72. PubMed ID: 18259947
[TBL] [Abstract][Full Text] [Related]
20. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
